PCRX
Pacira BioSciences, Inc.
NASDAQ NMS - GLOBAL MARKET· Pharmaceuticals· US· IPO 2011-02-03
$36.39
-0.01 (-0.03%)
last quote
Want the full multi-source brief on PCRX?
The agent pulls regulatory filings, news flow, prediction-market pricing, and macro context — then synthesizes what's not yet in the price.
Today
Open
$36.39
High
$36.41
Low
$36.39
Previous close
$36.40
Fundamentals
Market cap
$1.45B
P/E (TTM)
99.10x
P/S (TTM)
1.94x
P/B
1.61x
Gross margin
79.21%
Operating margin
1.06%
Net margin
1.96%
Rev growth (YoY)
5.71%
EPS growth (YoY)
—
ROE
2.13%
52W high
$36.66
52W low
$18.80
Beta
0.17x
Industry peers
by market cap
Upcoming earnings
next 30 days
2026-11-04today
Q3 2026EPS est $0.75Rev est $186.3M
Recent SEC filings
CIK 1396814filing-language history →
Recent news
2026-10-28 → 2026-11-04
Yahoo · 1d
Harrow (HROW) Expected to Beat Earnings Estimates: Should You Buy?
Harrow (HROW) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Yahoo · 5d
Viatris Announces Commencement of Tender Offer to Acquire Pacira BioSciences, Inc.
Viatris Inc. ("Viatris") (Nasdaq: VTRS), a global healthcare company, today announced that Peach Purchaser Sub Inc. ("Purchaser"), a wholly owned subsidiary of Viatris, has commenced a tender offer to purchase all of the issued and outstanding shares of common stock, par value $0.001 per share (the "Shares"), of Pacira BioSciences, Inc. ("Pacira") (Nasdaq: PCRX), for $36.50 per Share, in cash, net
Benzinga · 5d
Viatris Subsidiary Peach Purchaser Sub Commences Tender Offer To Acquire Pacira Biosciences For $36.50/Shr
Viatris Inc. ("Viatris") (NASDAQ:VTRS), a global healthcare company, today announced that Peach Purchaser Sub Inc. ("Purchaser"), a wholly owned subsidiary of Viatris, has commenced a tender offer to
Yahoo · 6d
Pacira BioSciences (PCRX) Reports Next Week: Wall Street Expects Earnings Growth
Pacira BioSciences (PCRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
This is the free preview
The agent layer adds regulatory-language drift detection, cross-venue prediction-market signals, macro overlays, programmable alert rules, overnight briefs, and a grounding verifier on every claim. 7-day Pro trial, no card required.
Start the trial